An update on the assessment and management of metabolic syndrome, a growing medical emergency in paediatric populations

Pharmacological Research

Volumn 119, Issue , 2017, Pages 99-117

  Mameli, Chiara ^a   Zuccotti, Gian Vincenzo ^a   Carnovale, Carla ^b   Galli, Erica ^a   Nannini, Pilar ^a   Cervia, Davide ^b,c   Perrotta, Cristiana ^b  

^a UNIVERSITY OF MILAN   (Italy)

^b UNIVERSITY OF MILAN   (Italy)

^c UNIVERSITY OF TUSCIA   (Italy)

Author keywords

ADRs; Lifestyle interventions; Metabolic syndrome; Paediatrics; Pharmacotherapy; Symptoms and diagnosis of metabolic syndrome

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ANTIDIABETIC AGENT; ANTIHYPERTENSIVE AGENT; ANTILIPEMIC AGENT; BILE ACID SEQUESTRANT; CREATINE KINASE; EXENDIN 4; EZETIMIBE; FIBRIC ACID DERIVATIVE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LIRAGLUTIDE; LORCASERIN; METFORMIN; NUTRACEUTICAL; TETRAHYDROLIPSTATIN; TOPIRAMATE;

ABDOMINAL DISCOMFORT; ABDOMINAL PAIN; ADIPOSE TISSUE; ADOLESCENT OBESITY; ADVERSE DRUG REACTION; ALTERNATIVE MEDICINE; APPENDICITIS; ATAXIA; BEHAVIOR DISORDER; BLURRED VISION; CARDIOMETABOLIC RISK; CARDIOVASCULAR DISEASE; CHILDHOOD OBESITY; CHOLECYSTITIS; CHOLELITHIASIS; CHRONIC KIDNEY FAILURE; CLINICAL OUTCOME; CONSENSUS; CONSTIPATION; CONVULSION; COUGHING; DATA BASE; DECREASED APPETITE; DEHYDRATION; DEPRESSION; DIARRHEA; DIET THERAPY; DISEASE ASSOCIATION; DISEASE MARKER; DISORDERS OF CARBOHYDRATE METABOLISM; DIZZINESS; DRUG SAFETY; DYSLIPIDEMIA; DYSPNEA; EMERGENCY CARE; EPISTAXIS; FACE EDEMA; FAMILIAL HYPERCHOLESTEROLEMIA; FATIGUE; FEVER; FIBROMATOSIS; FLATULENCE; FOOD AND DRUG ADMINISTRATION; GALLBLADDER DISEASE; GASTROINTESTINAL DISEASE; GASTROINTESTINAL SYMPTOM; HEADACHE; HEART VENTRICLE ARRHYTHMIA; HUMAN; HYPERGLYCEMIA; HYPERKALEMIA; HYPERTENSION; HYPERTRIGLYCERIDEMIA; HYPOGLYCEMIA; HYPOTENSION; INFLAMMATORY DISEASE; INSOMNIA; INSULIN RESISTANCE; KETOACIDOSIS; KINESIOTHERAPY; LACTIC ACIDOSIS; LOOSE FECES; MALAISE; METABOLIC SYNDROME X; MUSCLE CRAMP; MUSCLE TISSUE; MYALGIA; MYOPATHY; NAUSEA; NEPHROLITHIASIS; NON INSULIN DEPENDENT DIABETES MELLITUS; NONALCOHOLIC FATTY LIVER; NONHUMAN; OBESITY; ONSET AGE; OVARY POLYCYSTIC DISEASE; PATHOGENESIS; PATHOPHYSIOLOGY; PRACTICE GUIDELINE; PREVALENCE; PSYCHOSIS; PUBERTY; PUBLIC HEALTH SERVICE; QT PROLONGATION; RASH; RECTUM HEMORRHAGE; RETROSPECTIVE STUDY; REVIEW; RHABDOMYOLYSIS; RHINOPHARYNGITIS; SEXUAL MATURATION; SINUS ARRHYTHMIA; SLEEP PARAMETERS; SOMNOLENCE; SUICIDE ATTEMPT; TACHYCARDIA; THORAX PAIN; TREMOR; UNCONSCIOUSNESS; UPPER ABDOMINAL PAIN; UPPER RESPIRATORY TRACT INFECTION; VOMITING; ANIMAL; CHILD; COMPLICATION; EXERCISE; LIFESTYLE;

ANIMALS; CHILD; DIABETES MELLITUS, TYPE 2; DYSLIPIDEMIAS; EXERCISE; HUMANS; HYPERTENSION; LIFE STYLE; METABOLIC SYNDROME X; NON-ALCOHOLIC FATTY LIVER DISEASE; OBESITY;

EID: 85012277315     PISSN: 10436618     EISSN: 10961186     Source Type: Journal    
DOI: 10.1016/j.phrs.2017.01.017     Document Type: Review

References (242)

1. [1] Alberti, K.G., Zimmet, P., Shaw, J., Metabolic syndrome-a new world-wide definition. A consensus statement from the international diabetes federation. Diabet. Med. 23 (2006), 469–480.
2. [2] Grundy, S.M., Cleeman, J.I., Daniels, S.R., Donato, K.A., Eckel, R.H., Franklin, B.A., Gordon, D.J., Krauss, R.M., Savage, P.J., Smith, S.C. Jr., Spertus, J.A., Costa, F., Diagnosis and management of the metabolic syndrome: an american heart association/national heart, lung, and blood institute scientific statement. Circulation 112 (2005), 2735–2752.
3. [3] Cameron, A.J., Shaw, J.E., Zimmet, P.Z., The metabolic syndrome: prevalence in worldwide populations. Endocrinol. Metab. Clin. North Am. 33 (2004), 351–375 table of contents.
4. [4] Eckel, R.H., Grundy, S.M., Zimmet, P.Z., The metabolic syndrome. Lancet 365 (2005), 1415–1428.
5. [5] Cornier, M.A., Dabelea, D., Hernandez, T.L., Lindstrom, R.C., Steig, A.J., Stob, N.R., Van Pelt, R.E., Wang, H., Eckel, R.H., The metabolic syndrome. Endocr. Rev. 29 (2008), 777–822.
6. [6] Uzunlulu, M., Telci Caklili, O., Oguz, A., Association between metabolic syndrome and cancer. Ann. Nutr. Metab. 68 (2016), 173–179.
7. [7] Boudreau, D.M., Malone, D.C., Raebel, M.A., Fishman, P.A., Nichols, G.A., Feldstein, A.C., Boscoe, A.N., Ben-Joseph, R.H., Magid, D.J., Okamoto, L.J., Health care utilization and costs by metabolic syndrome risk factors. Metab. Syndr. Relat. Disord. 7 (2009), 305–314.
8. [8] Cook, S., Weitzman, M., Auinger, P., Nguyen, M., Dietz, W.H., Prevalence of a metabolic syndrome phenotype in adolescents: findings from the third national health and nutrition examination survey, 1988–1994. Arch. Pediatr. Adolesc. Med. 157 (2003), 821–827.
9. [9] Ford, E.S., Li, C., Defining the metabolic syndrome in children and adolescents: will the real definition please stand up. J. Pediatr. 152 (2008), 160–164.
10. [10] Zimmet, P., Alberti, G., Kaufman, F., Tajima, N., Silink, M., Arslanian, S., Wong, G., Bennett, P., Shaw, J., Caprio, S., The metabolic syndrome in children and adolescents. Lancet 369 (2007), 2059–2061.
11. [11] Tracy, R.E., Newman, W.P. 3rd, Wattigney, W.A., Srinivasan, S.R., Strong, J.P., Berenson, G.S., Histologic features of atherosclerosis and hypertension from autopsies of young individuals in a defined geographic population: the bogalusa heart study. Atherosclerosis 116 (1995), 163–179.
12. [12] Tobisch, B., Blatniczky, L., Barkai, L., Cardiometabolic risk factors and insulin resistance in obese children and adolescents: relation to puberty. Pediatr. Obes. 10 (2015), 37–44.
13. [13] Ahrens, W., Moreno, L.A., Marild, S., Molnar, D., Siani, A., De Henauw, S., Bohmann, J., Gunther, K., Hadjigeorgiou, C., Iacoviello, L., Lissner, L., Veidebaum, T., Pohlabeln, H., Pigeot, I., Metabolic syndrome in young children: definitions and results of the idefics study. Int. J. Obes. (Lond.) 38:Suppl. 2 (2014), S4–S14.
14. [14] Ahrens, W., Bammann, K., Siani, A., Buchecker, K., De Henauw, S., Iacoviello, L., Hebestreit, A., Krogh, V., Lissner, L., Marild, S., Molnar, D., Moreno, L.A., Pitsiladis, Y.P., Reisch, L., Tornaritis, M., Veidebaum, T., Pigeot, I., The idefics cohort: design, characteristics and participation in the baseline survey. Int. J. Obes. (Lond.) 35:Suppl. 1 (2011), S3–S15.
15. [15] Weiss, R., Bremer, A.A., Lustig, R.H., What is metabolic syndrome, and why are children getting it. Ann. N. Y. Acad. Sci. 1281 (2013), 123–140.
16. [16] Reinehr, T., Wolters, B., Knop, C., Lass, N., Holl, R.W., Strong effect of pubertal status on metabolic health in obese children: a longitudinal study. J. Clin. Endocrinol. Metab. 100 (2015), 301–308.
17. [17] Kelly, L.A., Lane, C.J., Weigensberg, M.J., Toledo-Corral, C.M., Goran, M.I., Pubertal changes of insulin sensitivity, acute insulin response, and beta-cell function in overweight latino youth. J. Pediatr. 158 (2011), 442–446.
18. [18] Goran, M.I., Gower, B.A., Longitudinal study on pubertal insulin resistance. Diabetes 50 (2001), 2444–2450.
19. [19] Reinehr, T., Metabolic syndrome in children and adolescents: a critical approach considering the interaction between pubertal stage and insulin resistance. Curr. Diabetes Rep., 16, 2016, 8.
20. [20] Weiss, R., Dziura, J., Burgert, T.S., Tamborlane, W.V., Taksali, S.E., Yeckel, C.W., Allen, K., Lopes, M., Savoye, M., Morrison, J., Sherwin, R.S., Caprio, S., Obesity and the metabolic syndrome in children and adolescents. N. Engl. J. Med. 350 (2004), 2362–2374.
21. [21] Viner, R.M., Segal, T.Y., Lichtarowicz-Krynska, E., Hindmarsh, P., Prevalence of the insulin resistance syndrome in obesity. Arch. Dis. Child 90 (2005), 10–14.
22. [22] Fitzpatrick, S.L., Lai, B.S., Brancati, F.L., Golden, S.H., Hill-Briggs, F., Metabolic syndrome risk profiles among african american adolescents: National health and nutrition examination survey, 2003–2010. Diabetes Care 36 (2013), 436–442.
23. [23] Osei, K., Metabolic syndrome in blacks: are the criteria right. Curr. Diabetes Rep. 10 (2010), 199–208.
24. [24] Sumner, A.E., Ethnic differences in triglyceride levels and high-density lipoprotein lead to underdiagnosis of the metabolic syndrome in black children and adults. J. Pediatr. 155 (2009), S7 e–11.
25. [25] Gurka, M.J., Lilly, C.L., Oliver, M.N., DeBoer, M.D., An examination of sex and racial/ethnic differences in the metabolic syndrome among adults: a confirmatory factor analysis and a resulting continuous severity score. Metabolism 63 (2014), 218–225.
26. [26] Reinehr, T., de Sousa, G., Toschke, A.M., Andler, W., Comparison of metabolic syndrome prevalence using eight different definitions: a critical approach. Arch. Dis. Child 92 (2007), 1067–1072.
27. [27] Royston, P., Altman, D.G., Sauerbrei, W., Dichotomizing continuous predictors in multiple regression: a bad idea. Stat. Med. 25 (2006), 127–141.
28. [28] Andersen, L.B., Lauersen, J.B., Brond, J.C., Anderssen, S.A., Sardinha, L.B., Steene-Johannessen, J., McMurray, R.G., Barros, M.V., Kriemler, S., Moller, N.C., Bugge, A., Kristensen, P.L., Ried-Larsen, M., Grontved, A., Ekelund, U., A new approach to define and diagnose cardiometabolic disorder in children. J. Diabetes Res., 2015, 2015, 539835.
29. [29] Hesse, M.B., Young, G., Murray, R.D., Evaluating health risk using a continuous metabolic syndrome score in obese children. J. Pediatr. Endocrinol. Metab. 29 (2016), 451–458.
30. [30] Eisenmann, J.C., Laurson, K.R., DuBose, K.D., Smith, B.K., Donnelly, J.E., Construct validity of a continuous metabolic syndrome score in children. Diabetol. Metab. Syndr., 2, 2010, 8.
31. [31] Shafiee, G., Kelishadi, R., Heshmat, R., Qorbani, M., Motlagh, M.E., Aminaee, T., Ardalan, G., Taslimi, M., Poursafa, P., Larijani, B., First report on the validity of a continuous metabolic syndrome score as an indicator for metabolic syndrome in a national sample of paediatric population – the caspian-iii study. Endokrynol. Pol. 64 (2013), 278–284.
32. [32] Okosun, I.S., Lyn, R., Davis-Smith, M., Eriksen, M., Seale, P., Validity of a continuous metabolic risk score as an index for modeling metabolic syndrome in adolescents. Ann. Epidemiol. 20 (2010), 843–851.
33. [33] Marcovecchio, M.L., Chiarelli, F., Metabolic syndrome in youth: chimera or useful concept. Curr. Diabetes Rep. 13 (2013), 56–62.
34. [34] Beltran-Sanchez, H., Harhay, M.O., Harhay, M.M., McElligott, S., Prevalence and trends of metabolic syndrome in the adult U.S. Population, 1999–2010. J. Am. Coll. Cardiol. 62 (2013), 697–703.
35. [35] Kanwar, P., Kowdley, K.V., The metabolic syndrome and its influence on nonalcoholic steatohepatitis. Clin. Liver Dis. 20 (2016), 225–243.
36. [36] Friend, A., Craig, L., Turner, S., The prevalence of metabolic syndrome in children: a systematic review of the literature. Metab. Syndr. Relat. Disord. 11 (2013), 71–80.
37. [37] Pan, Y., Pratt, C.A., Metabolic syndrome and its association with diet and physical activity in us adolescents. J. Am. Diet. Assoc. 108 (2008), 276–286 discussion 86.
38. [38] Cook, S., Auinger, P., Li, C., Ford, E.S., Metabolic syndrome rates in united states adolescents, from the national health and nutrition examination survey, 1999–2002. J. Pediatr. 152 (2008), 165–170.
39. [39] Castillo, E.H., Borges, G., Talavera, J.O., Orozco, R., Vargas-Aleman, C., Huitron-Bravo, G., Diaz-Montiel, J.C., Castanon, S., Salmeron, J., Body mass index and the prevalence of metabolic syndrome among children and adolescents in two mexican populations. J. Adolesc. Health 40 (2007), 521–526.
40. [40] Li, Y., Yang, X., Zhai, F., Kok, F.J., Zhao, W., Piao, J., Zhang, J., Cui, Z., Ma, G., Prevalence of the metabolic syndrome in chinese adolescents. Br. J. Nutr. 99 (2008), 565–570.
41. [41] Ekelund, U., Anderssen, S., Andersen, L.B., Riddoch, C.J., Sardinha, L.B., Luan, J., Froberg, K., Brage, S., Prevalence and correlates of the metabolic syndrome in a population-based sample of european youth. Am. J. Clin. Nutr. 89 (2009), 90–96.
42. [42] Pirkola, J., Tammelin, T., Bloigu, A., Pouta, A., Laitinen, J., Ruokonen, A., Tapanainen, P., Jarvelin, M.R., Vaarasmaki, M., Prevalence of metabolic syndrome at age 16 using the international diabetes federation paediatric definition. Arch. Dis. Child 93 (2008), 945–951.
43. [43] Tailor, A.M., Peeters, P.H., Norat, T., Vineis, P., Romaguera, D., An update on the prevalence of the metabolic syndrome in children and adolescents. Int. J. Pediatr. Obes. 5 (2010), 202–213.
44. [44] Reaven, G.M., Banting lecture 1988: role of insulin resistance in human disease. Diabetes 37 (1988), 1595–1607.
45. [45] Haffner, S.M., Epidemiology of insulin resistance and its relation to coronary artery disease. Am. J. Cardiol. 84 (1999), 11J–14J.
46. [46] Hu, F.B., Stampfer, M.J., Haffner, S.M., Solomon, C.G., Willett, W.C., Manson, J.E., Elevated risk of cardiovascular disease prior to clinical diagnosis of type 2 diabetes. Diabetes Care 25 (2002), 1129–1134.
47. [47] Alberti, K.G., Zimmet, P.Z., Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: diagnosis and classification of diabetes mellitus provisional report of a who consultation. Diabet. Med. 15 (1998), 539–553.
48. [48] Naimi, M., Gautier, N., Chaussade, C., Valverde, A.M., Accili, D., Van Obberghen, E., Nuclear forkhead box o1 controls and integrates key signaling pathways in hepatocytes. Endocrinology 148 (2007), 2424–2434.
49. [49] Brown, M.S., Goldstein, J.L., Selective versus total insulin resistance: a pathogenic paradox. Cell Metab. 7 (2008), 95–96.
50. [50] Ginsberg, H.N., Zhang, Y.L., Hernandez-Ono, A., Regulation of plasma triglycerides in insulin resistance and diabetes. Arch. Med. Res. 36 (2005), 232–240.
51. [51] Samuel, V.T., Petersen, K.F., Shulman, G.I., Lipid-induced insulin resistance: unravelling the mechanism. Lancet 375 (2010), 2267–2277.
52. [52] Gustafson, B., Hammarstedt, A., Andersson, C.X., Smith, U., Inflamed adipose tissue: a culprit underlying the metabolic syndrome and atherosclerosis. Arterioscler. Thromb. Vasc. Biol. 27 (2007), 2276–2283.
53. [53] Heilbronn, L.K., Campbell, L.V., Adipose tissue macrophages, low grade inflammation and insulin resistance in human obesity. Curr. Pharm. Des. 14 (2008), 1225–1230.
54. [54] Petersen, K.F., Dufour, S., Savage, D.B., Bilz, S., Solomon, G., Yonemitsu, S., Cline, G.W., Befroy, D., Zemany, L., Kahn, B.B., Papademetris, X., Rothman, D.L., Shulman, G.I., The role of skeletal muscle insulin resistance in the pathogenesis of the metabolic syndrome. Proc. Natl. Acad. Sci. U. S. A. 104 (2007), 12587–12594.
55. [55] Pilia, S., Casini, M.R., Foschini, M.L., Minerba, L., Musiu, M.C., Marras, V., Civolani, P., Loche, S., The effect of puberty on insulin resistance in obese children. J. Endocrinol. Invest. 32 (2009), 401–405.
56. [56] Agirbasli, M., Agaoglu, N.B., Orak, N., Caglioz, H., Ocek, T., Karabag, T., Baykan, O.A., Sex hormones, insulin resistance and high-density lipoprotein cholesterol levels in children. Horm. Res. Paediatr. 73 (2010), 166–174.
57. [57] de Sousa, G., Brodoswki, C., Kleber, M., Wunsch, R., Reinehr, T., Association between androgens, intima-media thickness and the metabolic syndrome in obese adolescent girls. Clin. Endocrinol. (Oxf.) 72 (2010), 770–774.
58. [58] Herbst, K.L., Amory, J.K., Brunzell, J.D., Chansky, H.A., Bremner, W.J., Testosterone administration to men increases hepatic lipase activity and decreases hdl and ldl size in 3 wk. Am. J. Physiol. Endocrinol. Metab. 284 (2003), E1112–8.
59. [59] Jurimae, J., Gruodyte, R., Saar, M., Cicchella, A., Stefanelli, C., Passariello, C., Maasalu, K., Jurimae, T., von Duvillard, S.P., Plasma visfatin and adiponectin concentrations in physically active adolescent girls: relationships with insulin sensitivity and body composition variables. J. Pediatr. Endocrinol. Metab. 24 (2011), 419–425.
60. [60] Rhie, Y.J., Choi, B.M., Eun, S.H., Son, C.S., Park, S.H., Lee, K.H., Association of serum retinol binding protein 4 with adiposity and pubertal development in korean children and adolescents. J. Korean Med. Sci. 26 (2011), 797–802.
61. [61] Korner, A., Neef, M., Friebe, D., Erbs, S., Kratzsch, J., Dittrich, K., Bluher, S., Kapellen, T.M., Kovacs, P., Stumvoll, M., Bluher, M., Kiess, W., Vaspin is related to gender, puberty and deteriorating insulin sensitivity in children. Int. J. Obes. (Lond.) 35 (2011), 578–586.
62. [62] Sorensen, K., Aksglaede, L., Munch-Andersen, T., Aachmann-Andersen, N.J., Petersen, J.H., Hilsted, L., Helge, J.W., Juul, A., Sex hormone-binding globulin levels predict insulin sensitivity, disposition index, and cardiovascular risk during puberty. Diabetes Care 32 (2009), 909–914.
63. [63] Reinehr, T., Elfers, C., Lass, N., Roth, C.L., Irisin and its relation to insulin resistance and puberty in obese children: a longitudinal analysis. J. Clin. Endocrinol. Metab. 100 (2015), 2123–2130.
64. [64] Korner, A., Kratzsch, J., Gausche, R., Schaab, M., Erbs, S., Kiess, W., New predictors of the metabolic syndrome in children–role of adipocytokines. Pediatr. Res. 61 (2007), 640–645.
65. [65] Cook, D.G., Mendall, M.A., Whincup, P.H., Carey, I.M., Ballam, L., Morris, J.E., Miller, G.J., Strachan, D.P., C-reactive protein concentration in children: relationship to adiposity and other cardiovascular risk factors. Atherosclerosis 149 (2000), 139–150.
66. [66] Oliveira, A.C., Oliveira, A.M., Adan, L.F., Oliveira, N.F., Silva, A.M., Ladeia, A.M., C-reactive protein and metabolic syndrome in youth: a strong relationship?. Obesity (Silver Spring) 16 (2008), 1094–1098.
67. [67] Hitze, B., Bosy-Westphal, A., Bielfeldt, F., Settler, U., Plachta-Danielzik, S., Pfeuffer, M., Schrezenmeir, J., Monig, H., Muller, M.J., Determinants and impact of sleep duration in children and adolescents: data of the kiel obesity prevention study. Eur. J. Clin. Nutr. 63 (2009), 739–746.
68. [68] Matthews, K.A., Dahl, R.E., Owens, J.F., Lee, L., Hall, M., Sleep duration and insulin resistance in healthy black and white adolescents. Sleep 35 (2012), 1353–1358.
69. [69] Koren, D., O'Sullivan, K.L., Mokhlesi, B., Metabolic and glycemic sequelae of sleep disturbances in children and adults. Curr. Diabetes Rep., 15, 2015, 562.
70. [70] Androutsos, O., Moschonis, G., Mavrogianni, C., Roma-Giannikou, E., Chrousos, G.P., Kanaka-Gantenbein, C., Manios, Y., Identification of lifestyle patterns, including sleep deprivation, associated with insulin resistance in children: the healthy growth study. Eur. J. Clin. Nutr. 68 (2014), 344–349.
71. [71] Javaheri, S., Storfer-Isser, A., Rosen, C.L., Redline, S., Association of short and long sleep durations with insulin sensitivity in adolescents. J. Pediatr. 158 (2011), 617–623.
72. [72] Stancakova, A., Laakso, M., Genetics of metabolic syndrome. Rev. Endocr. Metab. Disord. 15 (2014), 243–252.
73. [73] Kraja, A.T., Vaidya, D., Pankow, J.S., Goodarzi, M.O., Assimes, T.L., Kullo, I.J., Sovio, U., Mathias, R.A., Sun, Y.V., Franceschini, N., Absher, D., Li, G., Zhang, Q., Feitosa, M.F., Glazer, N.L., Haritunians, T., Hartikainen, A.L., Knowles, J.W., North, K.E., Iribarren, C., Kral, B., Yanek, L., O'Reilly, P.F., McCarthy, M.I., Jaquish, C., Couper, D.J., Chakravarti, A., Psaty, B.M., Becker, L.C., Province, M.A., Boerwinkle, E., Quertermous, T., Palotie, L., Jarvelin, M.R., Becker, D.M., Kardia, S.L., Rotter, J.I., Chen, Y.D., Borecki, I.B., A bivariate genome-wide approach to metabolic syndrome: stampeed consortium. Diabetes 60 (2011), 1329–1339.
74. [74] Avery, C.L., He, Q., North, K.E., Ambite, J.L., Boerwinkle, E., Fornage, M., Hindorff, L.A., Kooperberg, C., Meigs, J.B., Pankow, J.S., Pendergrass, S.A., Psaty, B.M., Ritchie, M.D., Rotter, J.I., Taylor, K.D., Wilkens, L.R., Heiss, G., Lin, D.Y., A phenomics-based strategy identifies loci on apoc1, brap, and plcg1 associated with metabolic syndrome phenotype domains. PLoS Genet., 7, 2011, e1002322.
75. [75] Jeong, S.W., Chung, M., Park, S.J., Cho, S.B., Hong, K.W., Genome-wide association study of metabolic syndrome in koreans. Genom. Inform. 12 (2014), 187–194.
76. [76] Tekola-Ayele, F., Doumatey, A.P., Shriner, D., Bentley, A.R., Chen, G., Zhou, J., Fasanmade, O., Johnson, T., Oli, J., Okafor, G., Eghan, B.A. Jr., Agyenim-Boateng, K., Adebamowo, C., Amoah, A., Acheampong, J., Adeyemo, A., Rotimi, C.N., Genome-wide association study identifies african-ancestry specific variants for metabolic syndrome. Mol. Genet. Metab. 116 (2015), 305–313.
77. [77] Brown, A.E., Walker, M., Genetics of insulin resistance and the metabolic syndrome. Curr. Cardiol. Rep., 18, 2016, 75.
78. [78] Fernandez, J.R., Redden, D.T., Pietrobelli, A., Allison, D.B., Waist circumference percentiles in nationally representative samples of african-american, european-american, and mexican-american children and adolescents. J. Pediatr. 145 (2004), 439–444.
79. [79] Janssen, I., Katzmarzyk, P.T., Srinivasan, S.R., Chen, W., Malina, R.M., Bouchard, C., Berenson, G.S., Combined influence of body mass index and waist circumference on coronary artery disease risk factors among children and adolescents. Pediatrics 115 (2005), 1623–1630.
80. [80] Brambilla, P., Bedogni, G., Moreno, L.A., Goran, M.I., Gutin, B., Fox, K.R., Peters, D.M., Barbeau, P., De Simone, M., Pietrobelli, A., Crossvalidation of anthropometry against magnetic resonance imaging for the assessment of visceral and subcutaneous adipose tissue in children. Int. J. Obes. (Lond.) 30 (2006), 23–30.
81. [81] Khoury, M., Manlhiot, C., McCrindle, B.W., Role of the waist/height ratio in the cardiometabolic risk assessment of children classified by body mass index. J. Am. Coll. Cardiol. 62 (2013), 742–751.
82. [82] Nambiar, S., Truby, H., Davies, P.S., Baxter, K., Use of the waist-height ratio to predict metabolic syndrome in obese children and adolescents. J. Paediatr. Child Health 49 (2013), E281–7.
83. [83] Urbina, E.M., Khoury, P.R., McCoy, C.E., Dolan, L.M., Daniels, S.R., Kimball, T.R., Triglyceride to hdl-c ratio and increased arterial stiffness in children, adolescents, and young adults. Pediatrics 131 (2013), e1082–90.
84. [84] Burns, S.F., Lee, S.J., Arslanian, S.A., Surrogate lipid markers for small dense low-density lipoprotein particles in overweight youth. J. Pediatr. 161 (2012), 991–996.
85. [85] Magnussen, C.G., Koskinen, J., Juonala, M., Chen, W., Srinivasan, S.R., Sabin, M.A., Thomson, R., Schmidt, M.D., Nguyen, Q.M., Xu, J.H., Skilton, M.R., Kahonen, M., Laitinen, T., Taittonen, L., Lehtimaki, T., Ronnemaa, T., Viikari, J.S., Berenson, G.S., Raitakari, O.T., A diagnosis of the metabolic syndrome in youth that resolves by adult life is associated with a normalization of high carotid intima-media thickness and type 2 diabetes mellitus risk: the bogalusa heart and cardiovascular risk in young finns studies. J. Am. Coll. Cardiol. 60 (2012), 1631–1639.
86. [86] Sun, S.S., Liang, R., Huang, T.T., Daniels, S.R., Arslanian, S., Liu, K., Grave, G.D., Siervogel, R.M., Childhood obesity predicts adult metabolic syndrome: the fels longitudinal study. J. Pediatr. 152 (2008), 191–200.
87. [87] Wittcopp, C., Conroy, R., Metabolic syndrome in children and adolescents. Pediatr. Rev. 37 (2016), 193–202.
88. [88] Coviello, A.D., Legro, R.S., Dunaif, A., Adolescent girls with polycystic ovary syndrome have an increased risk of the metabolic syndrome associated with increasing androgen levels independent of obesity and insulin resistance. J. Clin. Endocrinol. Metab. 91 (2006), 492–497.
89. [89] Bremer, A.A., Polycystic ovary syndrome in the pediatric population. Metab. Syndr. Relat. Disord. 8 (2010), 375–394.
90. [90] Kubo, T., Common approach to childhood obesity in japan. J. Pediatr. Endocrinol. Metab. 27 (2014), 581–592.
91. [91] Reinehr, T., Lifestyle intervention in childhood obesity: changes and challenges. Nat. Rev. Endocrinol. 9 (2013), 607–614.
92. [92] Bass, R., Eneli, I., Severe childhood obesity: an under-recognised and growing health problem. Postgrad. Med. J. 91 (2015), 639–645.
93. [93] Pacifico, L., Anania, C., Martino, F., Poggiogalle, E., Chiarelli, F., Arca, M., Chiesa, C., Management of metabolic syndrome in children and adolescents. Nutr. Metab. Cardiovasc. Dis. 21 (2011), 455–466.
94. [94] Owens, S., Galloway, R., Childhood obesity and the metabolic syndrome. Curr. Atheroscler. Rep., 16, 2014, 436.
95. [95] Monzani, A., Rapa, A., Fuiano, N., Diddi, G., Prodam, F., Bellone, S., Bona, G., Metabolic syndrome is strictly associated with parental obesity beginning from childhood. Clin. Endocrinol. (Oxf.) 81 (2014), 45–51.
96. [96] Wennberg, M., Gustafsson, P.E., Wennberg, P., Hammarstrom, A., Poor breakfast habits in adolescence predict the metabolic syndrome in adulthood. Public Health Nutr. 18 (2015), 122–129.
97. [97] Lee, A.M., Gurka, M.J., DeBoer, M.D., Trends in metabolic syndrome severity and lifestyle factors among adolescents. Pediatrics, 137, 2016, e20153177.
98. [98] Lazorick, S., Crawford, Y., Gilbird, A., Fang, X., Burr, V., Moore, V., Hardison, G.T. Jr., Long-term obesity prevention and the motivating adolescents with technology to choose health program. Child. Obes. 10 (2014), 25–33.
99. [99] Nemet, D., Ben-Haim, I., Pantanowits, M., Eliakim, A., Effects of a combined intervention for treating severely obese prepubertal children. J. Pediatr. Endocrinol. Metab. 26 (2013), 91–96.
100. [100] Andersen, C.J., Fernandez, M.L., Dietary strategies to reduce metabolic syndrome. Rev. Endocr. Metab. Disord. 14 (2013), 241–254.
101. [101] Nupponen, M., Pahkala, K., Juonala, M., Magnussen, C.G., Niinikoski, H., Ronnemaa, T., Viikari, J.S.A., Saarinen, M., Lagstrom, H., Jula, A., Simell, O., Raitakari, O.T., Metabolic syndrome from adolescence to early adulthood effect of infancy-onset dietary counseling of low saturated fat: the special turku coronary risk factor intervention project (strip). Circulation, 131, 2015 605-U40.
102. [102] Saneei, P., Hashemipour, M., Kelishadi, R., Rajaei, S., Esmaillzadeh, A., Effects of recommendations to follow the dietary approaches to stop hypertension (dash) diet v: usual dietary advice on childhood metabolic syndrome: a randomised cross-over clinical trial. Br. J. Nutr. 110 (2013), 2250–2259.
103. [103] Asghari, G., Yuzbashian, E., Mirmiran, P., Hooshmand, F., Najafi, R., Azizi, F., Dietary approaches to stop hypertension (dash) dietary pattern is associated with reduced incidence of metabolic syndrome in children and adolescents. J. Pediatr. 174 (2016), 178–184 e1.
104. [104] van de Laar, R.J., Stehouwer, C.D., van Bussel, B.C., Prins, M.H., Twisk, J.W., Ferreira, I., Adherence to a mediterranean dietary pattern in early life is associated with lower arterial stiffness in adulthood: the amsterdam growth and health longitudinal study. J. Intern. Med. 273 (2013), 79–93.
105. [105] Velazquez-Lopez, L., Santiago-Diaz, G., Nava-Hernandez, J., Munoz-Torres, A.V., Medina-Bravo, P., Torres-Tamayo, M., Mediterranean-style diet reduces metabolic syndrome components in obese children and adolescents with obesity. BMC Pediatr., 14, 2014, 175.
106. [106] Damsgaard, C.T., Ritz, C., Dalskov, S.M., Landberg, R., Stark, K.D., Biltoft-Jensen, A., Tetens, I., Astrup, A., Michaelsen, K.F., Lauritzen, L., Associations between school meal-induced dietary changes and metabolic syndrome markers in 8–11-year-old danish children. Eur. J. Nutr. 55 (2016), 1973–1984.
107. [107] Bravata, D.M., Sanders, L., Huang, J., Krumholz, H.M., Olkin, I., Gardner, C.D., Bravata, D.M., Efficacy and safety of low-carbohydrate diets: a systematic review. JAMA 289 (2003), 1837–1850.
108. [108] Wang, J., Light, K., Henderson, M., O'Loughlin, J., Mathieu, M.E., Paradis, G., Gray-Donald, K., Consumption of added sugars from liquid but not solid sources predicts impaired glucose homeostasis and insulin resistance among youth at risk of obesity. J. Nutr. 144 (2014), 81–86.
109. [109] Chan, T.F., Lin, W.T., Huang, H.L., Lee, C.Y., Wu, P.W., Chiu, Y.W., Huang, C.C., Tsai, S., Lin, C.L., Lee, C.H., Consumption of sugar-sweetened beverages is associated with components of the metabolic syndrome in adolescents. Nutrients 6 (2014), 2088–2103.
110. [110] Mirza, N.M., Palmer, M.G., Sinclair, K.B., McCarter, R., He, J., Ebbeling, C.B., Ludwig, D.S., Yanovski, J.A., Effects of a low glycemic load or a low-fat dietary intervention on body weight in obese hispanic american children and adolescents: a randomized controlled trial. Am. J. Clin. Nutr. 97 (2013), 276–285.
111. [111] Suskind, R.M., Blecker, U., Udall, J.N. Jr., von Almen, T.K., Schumacher, H.D., Carlisle, L., Sothern, M.S., Recent advances in the treatment of childhood obesity. Pediatr. Diabetes 1 (2000), 23–33.
112. [112] Damsgaard, C.T., Papadaki, A., Jensen, S.M., Ritz, C., Dalskov, S.M., Hlavaty, P., Saris, W.H., Martinez, J.A., Handjieva-Darlenska, T., Andersen, M.R., Stender, S., Larsen, T.M., Astrup, A., Molgaard, C., Michaelsen, K.F., Diogenes Higher protein diets consumed ad libitum improve cardiovascular risk markers in children of overweight parents from eight european countries. J. Nutr. 143 (2013), 810–817.
113. [113] Sabate, J., Wien, M., A perspective on vegetarian dietary patterns and risk of metabolic syndrome. Br. J. Nutr. 113:Suppl. 2 (2015), S136–S143.
114. [114] Carlson, J.J., Eisenmann, J.C., Norman, G.J., Ortiz, K.A., Young, P.C., Dietary fiber and nutrient density are inversely associated with the metabolic syndrome in us adolescents. J. Am. Diet. Assoc. 111 (2011), 1688–1695.
115. [115] Berkowitz, R.I., Wadden, T.A., Gehrman, C.A., Bishop-Gilyard, C.T., Moore, R.H., Womble, L.G., Cronquist, J.L., Trumpikas, N.L., Levitt Katz LE, Xanthopoulos MS. Meal replacements in the treatment of adolescent obesity: a randomized controlled trial. Obesity 19 (2011), 1193–1199.
116. [116] Guinhouya, B.C., Samouda, H., Zitouni, D., Vilhelm, C., Hubert, H., Evidence of the influence of physical activity on the metabolic syndrome and/or on insulin resistance in pediatric populations: a systematic review. Int. J. Pediatr. Obes. IJPO 6 (2011), 361–388.
117. [117] He, D., Xi, B., Xue, J., Huai, P., Zhang, M., Li, J., Association between leisure time physical activity and metabolic syndrome: a meta-analysis of prospective cohort studies. Endocrine 46 (2014), 231–240.
118. [118] Heshmat, R., Shafiee, G., Kelishadi, R., Babaki, A.E., Motlagh, M.E., Arefirad, T., Ardalan, G., Ataie-Jafari, A., Asayesh, H., Mohammadi, R., Qorbani, M., Is the association of continuous metabolic syndrome risk score with body mass index independent of physical activity? The caspian-iii study. Nutr. Res. Pract. 9 (2015), 404–410.
119. [119] Mendoza, J.A., Liu, Y., Active commuting to elementary school and adiposity: an observational study. Child. Obes. 10 (2014), 34–41.
120. [120] Wennberg, P., Gustafsson, P.E., Dunstan, D.W., Wennberg, M., Hammarstrom, A., Television viewing and low leisure-time physical activity in adolescence independently predict the metabolic syndrome in mid-adulthood. Diabetes Care 36 (2013), 2090–2097.
121. [121] Schmidt, M.D., Magnussen, C.G., Rees, E., Dwyer, T., Venn, A.J., Childhood fitness reduces the long-term cardiometabolic risks associated with childhood obesity. Int. J. Obes. 40 (2016), 1134–1140.
122. [122] Neto, A. Stabelini, de Campos, W., Dos Santos, G.C., Junior, O. Mazzardo, Metabolic syndrome risk score and time expended in moderate to vigorous physical activity in adolescents. BMC Pediatr., 14, 2014, 42.
123. [123] Taverno Ross, S.E., Byun, W., Dowda, M., McIver, K.L., Saunders, R.P., Pate, R.R., Sedentary behaviors in fifth-grade boys and girls: where, with whom, and why?. Child. Obes. 9 (2013), 532–539.
124. [124] Gutin, B., Owens, S., The influence of physical activity on cardiometabolic biomarkers in youths: a review. Pediatr. Exerc. Sci. 23 (2011), 169–185.
125. [125] Racil, G., Ounis, O. Ben, Hammouda, O., Kallel, A., Zouhal, H., Chamari, K., Amri, M., Effects of high vs. Moderate exercise intensity during interval training on lipids and adiponectin levels in obese young females. Eur. J. Appl. Physiol. 113 (2013), 2531–2540.
126. [126] Davis, A.M., Daldalian, M.C., Mayfield, C.A., Dean, K., Black, W.R., Sampilo, M.L., Gonzalez-Mijares, M., Suminski, R., Outcomes from an urban pediatric obesity program targeting minority youth: the healthy hawks program. Child. Obes. 9 (2013), 492–500.
127. [127] Rieder, J., Khan, U.I., Heo, M., Mossavar-Rahmani, Y., Blank, A.E., Strauss, T., Viswanathan, N., Wylie-Rosett, J., Evaluation of a community-based weight management program for predominantly severely obese, difficult-to-reach, inner-city minority adolescents. Child. Obes. 9 (2013), 292–304.
128. [128] Carraway, M.E., Lutes, L.D., Crawford, Y., Pratt, K.J., McMillan, A.G., Scripture, L.G., Henes, S., Cox, J., Vos, P., Collier, D.N., Camp-based immersion treatment for obese, low socioeconomic status, multi-ethnic adolescents. Child. Obes. 10 (2014), 122–131.
129. [129] Roberts, C.K., Izadpanah, A., Angadi, S.S., Barnard, R.J., Effects of an intensive short-term diet and exercise intervention: comparison between normal-weight and obese children. Am. J. Physiol. Regul. Integr. Comp. Physiol. 305 (2013), R552–R557.
130. [130] Africa, J.A., Newton, K.P., Schwimmer, J.B., Lifestyle interventions including nutrition, exercise, and supplements for nonalcoholic fatty liver disease in children. Dig. Dis. Sci. 61 (2016), 1375–1386.
131. [131] Gibson, P.S., Lang, S., Gilbert, M., Kamat, D., Bansal, S., Ford-Adams, M.E., Desai, A.P., Dhawan, A., Fitzpatrick, E., Moore, J.B., Hart, K.H., Assessment of diet and physical activity in paediatric non-alcoholic fatty liver disease patients: a United Kingdom case control study. Nutrients 7 (2015), 9721–9733.
132. [132] Rahimlou, M., Ahmadnia, H., Hekmatdoost, A., Dietary supplements and pediatric non-alcoholic fatty liver disease: present and the future. World J. Hepatol. 7 (2015), 2597–2602.
133. [133] Vilchis-Gil, J., Galvan-Portillo, M., Klunder-Klunder, M., Cruz, M., Flores-Huerta, S., Food habits, physical activities and sedentary lifestyles of eutrophic and obese school children: a case-control study. BMC Public Health, 15, 2015, 124.
134. [134] Santini, A., Tenore, G.C., Nutraceuticals, Novellino E., A paradigm of proactive medicine. Eur. J. Pharm. Sci. 96 (2016), 53–61.
135. [135] Davi, G., Santilli, F., Patrono, C., Nutraceuticals in diabetes and metabolic syndrome. Cardiovasc. Ther. 28 (2010), 216–226.
136. [136] Amiot, M.J., Riva, C., Vinet, A., Effects of dietary polyphenols on metabolic syndrome features in humans: a systematic review. Obes. Rev. 17 (2016), 573–586.
137. [137] Cicero, A.F., Colletti, A., Role of phytochemicals in the management of metabolic syndrome. Phytomed. Int. J. Phytother. Phytopharmacol. 23 (2016), 1134–1144.
138. [138] Kaur, G., Mukundan, S., Wani, V., Kumar, M.S., Nutraceuticals in the management and prevention of metabolic syndrome. Austin J. Pharmacol. Ther., 3, 2015, 1063.
139. [139] Cicero, A.F., Tartagni, E., Ertek, S., Nutraceuticals for metabolic syndrome management: from laboratory to benchside. Curr. Vasc. Pharmacol. 12 (2014), 565–571.
140. [140] Najm, W., Lie, D., Herbals used for diabetes, obesity, and metabolic syndrome. Prim. Care, 37, 2010, 237.
141. [141] Matsumoto, S., Nakanishi, R., Li, D., Alani, A., Rezaeian, P., Prabhu, S., Abraham, J., Fahmy, M.A., Dailing, C., Flores, F., Hamal, S., Broersen, A., Kitslaar, P.H., Budoff, M.J., Aged garlic extract reduces low attenuation plaque in coronary arteries of patients with metabolic syndrome in a prospective randomized double-blind study. J. Nutr. 146 (2016), 427S–432S.
142. [142] Al-Dughaishi, T., Nikolic, D., Zadjali, F., Al-Hashmi, K., Al-Waili, K., Rizzo, M., Al-Rasadi, K., Nutraceuticals as lipid-lowering treatment in pregnancy and their effects on the metabolic syndrome. Curr. Pharm. Biotechnol. 17 (2016), 614–623.
143. [143] Rios-Hoyo, A., Cortes, M.J., Rios-Ontiveros, H., Meaney, E., Ceballos, G., Gutierrez-Salmean, G., Obesity, metabolic syndrome, and dietary therapeutical approaches with a special focus on nutraceuticals (polyphenols): a mini-review. research. Int. J. Vitam. Nutr. 84 (2014), 113–123.
144. [144] O'Neil, C.E., Nicklas, T.A., Rampersaud, G.C., Fulgoni, V.L., 100% orange juice consumption is associated with better diet quality, improved nutrient adequacy, decreased risk for obesity, and improved biomarkers of health in adults: national health and nutrition examination survey, 2003–2006. Nutr. J., 11(107), 2012, 107.
145. [145] Saez-Lara, M.J., Robles-Sanchez, C., Ruiz-Ojeda, F.J., Plaza-Diaz, J., Gil, A., Effects of probiotics and synbiotics on obesity, insulin resistance syndrome, type 2 diabetes and non-alcoholic fatty liver disease: a review of human clinical trials. Int. J. Mol. Sci., 17, 2016.
146. [146] Festi, D., Schiumerini, R., Eusebi, L.H., Marasco, G., Taddia, M., Colecchia, A., Gut microbiota and metabolic syndrome. World J. Gastroenterol. 20 (2014), 16079–16094.
147. [147] Dennison, B.A., Levine, D.M., Randomized, double-blind, placebo-controlled, two-period crossover clinical trial of psyllium fiber in children with hypercholesterolemia. J. Pediatr. 123 (1993), 24–29.
148. [148] Davidson, M.H., Dugan, L.D., Burns, J.H., Sugimoto, D., Story, K., Drennan, K., A psyllium-enriched cereal for the treatment of hypercholesterolemia in children: a controlled, double-blind, crossover study. Am. J. Clin. Nutr. 63 (1996), 96–102.
149. [149] McCrindle, B.W., Urbina, E.M., Dennison, B.A., Jacobson, M.S., Steinberger, J., Rocchini, A.P., Hayman, L.L., Daniels, S.R., American Heart Association Atherosclerosis H, Obesity in Youth C, American Heart Association Council of Cardiovascular Disease in the Y, American Heart Association Council on Cardiovascular N, Drug therapy of high-risk lipid abnormalities in children and adolescents: a scientific statement from the american heart association atherosclerosis, hypertension, and obesity in youth committee, council of cardiovascular disease in the young, with the council on cardiovascular nursing. Circulation 115 (2007), 1948–1967.
150. [150] Widhalm, K., Brazda, G., Schneider, B., Kohl, S., Effect of soy protein diet versus standard low fat, low cholesterol diet on lipid and lipoprotein levels in children with familial or polygenic hypercholesterolemia. J. Pediatr. 123 (1993), 30–34.
151. [151] Gulesserian, T., Widhalm, K., Effect of a rapeseed oil substituting diet on serum lipids and lipoproteins in children and adolescents with familial hypercholesterolemia. J. Am. Coll. Nutr. 21 (2002), 103–108.
152. [152] Tammi, A., Ronnemaa, T., Gylling, H., Rask-Nissila, L., Viikari, J., Tuominen, J., Pulkki, K., Simell, O., Plant stanol ester margarine lowers serum total and low-density lipoprotein cholesterol concentrations of healthy children: the strip project. Special turku coronary risk factors intervention project. J. Pediatr. 136 (2000), 503–510.
153. [153] Gylling, H., Siimes, M.A., Miettinen, T.A., Sitostanol ester margarine in dietary treatment of children with familial hypercholesterolemia. J. Lipid Res. 36 (1995), 1807–1812.
154. [154] Pacifico, L., Giansanti, S., Gallozzi, A., Chiesa, C., Long chain omega-3 polyunsaturated fatty acids in pediatric metabolic syndrome. Mini Rev. Med. Chem. 14 (2014), 791–804.
155. [155] Engler, M.M., Engler, M.B., Malloy, M.J., Paul, S.M., Kulkarni, K.R., Mietus-Snyder, M.L., Effect of docosahexaenoic acid on lipoprotein subclasses in hyperlipidemic children (the early study). Am. J. Cardiol. 95 (2005), 869–871.
156. [156] Janczyk, W., Lebensztejn, D., Wierzbicka-Rucinska, A., Mazur, A., Neuhoff-Murawska, J., Matusik, P., Socha, P., Omega-3 fatty acids therapy in children with nonalcoholic fatty liver disease: a randomized controlled trial. J. Pediatr. 166 (2015), 1358–1363 e1-3.
157. [157] Kelishadi, R., Salek, S., Salek, M., Hashemipour, M., Movahedian, M., Effects of vitamin d supplementation on insulin resistance and cardiometabolic risk factors in children with metabolic syndrome: a triple-masked controlled trial. Jornal de pediatria 90 (2014), 28–34.
158. [158] Petersen, R.A., Dalskov, S.M., Sorensen, L.B., Hjorth, M.F., Andersen, R., Tetens, I., Krarup, H., Ritz, C., Astrup, A., Michaelsen, K.F., Molgaard, C., Damsgaard, C.T., Vitamin d status is associated with cardiometabolic markers in 8–11-year-old children, independently of body fat and physical activity. Br. J. Nutr. 114 (2015), 1647–1655.
159. [159] Lavine, J.E., Schwimmer, J.B., Van Natta, M.L., Molleston, J.P., Murray, K.F., Rosenthal, P., Abrams, S.H., Scheimann, A.O., Sanyal, A.J., Chalasani, N., Tonascia, J., Unalp, A., Clark, J.M., Brunt, E.M., Kleiner, D.E., Hoofnagle, J.H., Robuck, P.R., Nonalcoholic Steatohepatitis Clinical Research N, Effect of vitamin e or metformin for treatment of nonalcoholic fatty liver disease in children and adolescents: the tonic randomized controlled trial. JAMA 305 (2011), 1659–1668.
160. [160] Guerciolini, R., Mode of action of orlistat. Int. J. Obes. Relat. Metab. Disord. 21:Suppl. 3 (1997), S12–23.
161. [161] Matson, K.L., Fallon, R.M., Treatment of obesity in children and adolescents. J. Pediatr. Pharmacol. Ther. 17 (2012), 45–57.
162. [162] Viner, R.M., Hsia, Y., Tomsic, T., Wong, I.C., Efficacy and safety of anti-obesity drugs in children and adolescents: systematic review and meta-analysis. Obes. Rev. 11 (2010), 593–602.
163. [163] Czernichow, S., Lee, C.M., Barzi, F., Greenfield, J.R., Baur, L.A., Chalmers, J., Woodward, M., Huxley, R.R., Efficacy of weight loss drugs on obesity and cardiovascular risk factors in obese adolescents: a meta-analysis of randomized controlled trials. Obes. Rev. 11 (2010), 150–158.
164. [164] Madiraju, A.K., Erion, D.M., Rahimi, Y., Zhang, X.M., Braddock, D.T., Albright, R.A., Prigaro, B.J., Wood, J.L., Bhanot, S., MacDonald, M.J., Jurczak, M.J., Camporez, J.P., Lee, H.Y., Cline, G.W., Samuel, V.T., Kibbey, R.G., Shulman, G.I., Metformin suppresses gluconeogenesis by inhibiting mitochondrial glycerophosphate dehydrogenase. Nature 510 (2014), 542–546.
165. [165] Freemark, M., Bursey, D., The effects of metformin on body mass index and glucose tolerance in obese adolescents with fasting hyperinsulinemia and a family history of type 2 diabetes. Pediatrics, 107, 2001, E55.
166. [166] Love-Osborne, K., Sheeder, J., Zeitler, P., Addition of metformin to a lifestyle modification program in adolescents with insulin resistance. J. Pediatr. 152 (2008), 817–822.
167. [167] Wilson, D.M., Abrams, S.H., Aye, T., Lee, P.D., Lenders, C., Lustig, R.H., Osganian, S.V., Feldman, H.A., Metformin extended release treatment of adolescent obesity: a 48-week randomized, double-blind, placebo-controlled trial with 48-week follow-up. Arch. Pediatr. Adolesc. Med. 164 (2010), 116–123.
168. [168] Pramyothin, P., Khaodhiar, L., Metabolic syndrome with the atypical antipsychotics. Curr. Opin. Endocrinol. Diabetes Obes. 17 (2010), 460–466.
169. [169] Copeland, K.C., Silverstein, J., Moore, K.R., Prazar, G.E., Raymer, T., Shiffman, R.N., Springer, S.C., Thaker, V.V., Anderson, M., Spann, S.J., Flinn, S.K., Management of newly diagnosed type 2 diabetes mellitus (t2dm) in children and adolescents. Pediatrics 131 (2013), 364–382.
170. [170] Cali, A.M., Pierpont, B.M., Taksali, S.E., Allen, K., Shaw, M.M., Savoye, M., Caprio, S., Rosiglitazone improves glucose metabolism in obese adolescents with impaired glucose tolerance: a pilot study. Obesity (Silver Spring) 19 (2011), 94–99.
171. [171] Nissen, S.E., Wolski, K., Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N. Engl. J. Med. 356 (2007), 2457–2471.
172. [172] Standards of medical care in diabetes–2014. Diabetes Care 37:Suppl. 1 (2014), S14–S80.
173. [173] Kelly, A.S., Metzig, A.M., Rudser, K.D., Fitch, A.K., Fox, C.K., Nathan, B.M., Deering, M.M., Schwartz, B.L., Abuzzahab, M.J., Gandrud, L.M., Moran, A., Billington, C.J., Schwarzenberg, S.J., Exenatide as a weight-loss therapy in extreme pediatric obesity: a randomized, controlled pilot study. Obesity (Silver Spring) 20 (2012), 364–370.
174. [174] Kelly, A.S., Rudser, K.D., Nathan, B.M., Fox, C.K., Metzig, A.M., Coombes, B.J., Fitch, A.K., Bomberg, E.M., Abuzzahab, M.J., The effect of glucagon-like peptide-1 receptor agonist therapy on body mass index in adolescents with severe obesity: s randomized, placebo-controlled, clinical trial. JAMA Pediatr. 167 (2013), 355–360.
175. [175] Klein, D.J., Battelino, T., Chatterjee, D.J., Jacobsen, L.V., Hale, P.M., Arslanian, S., Liraglutide's safety, tolerability, pharmacokinetics, and pharmacodynamics in pediatric type 2 diabetes: a randomized, double-blind, placebo-controlled trial. Diabetes Technol. Ther. 16 (2014), 679–687.
176. [176] Braamskamp, M.J., Stefanutti, C., Langslet, G., Drogari, E., Wiegman, A., Hounslow, N., Kastelein, J.J., Efficacy and safety of pitavastatin in children and adolescents at high future cardiovascular risk. J. Pediatr. 167 (2015), 338–343 e5.
177. [177] Luirink, I.K., Hutten, B.A., Wiegman, A., Optimizing treatment of familial hypercholesterolemia in children and adolescents. Curr. Cardiol. Rep., 17, 2015, 629.
178. [178] Sweeney, M.E., Ezetimibe, Johnson R.R., An update on the mechanism of action, pharmacokinetics and recent clinical trials. Expert Opin. Drug Metab. Toxicol. 3 (2007), 441–450.
179. [179] van der Graaf, A., Cuffie-Jackson, C., Vissers, M.N., Trip, M.D., Gagne, C., Shi, G., Veltri, E., Avis, H.J., Kastelein, J.J., Efficacy and safety of coadministration of ezetimibe and simvastatin in adolescents with heterozygous familial hypercholesterolemia. J. Am. Coll. Cardiol. 52 (2008), 1421–1429.
180. [180] Araujo, M.B., Botto, P.M., Mazza, C.S., Use of ezetimibe in the treatment of familial hypercholesterolemia in children and adolescents. An. Pediatr. (Barc.) 77 (2012), 37–42.
181. [181] Kusters, D.M., Caceres, M., Coll, M., Cuffie, C., Gagne, C., Jacobson, M.S., Kwiterovich, P.O., Lee, R., Lowe, R.S., Massaad, R., McCrindle, B.W., Musliner, T.A., Triscari, J., Kastelein, J.J., Efficacy and safety of ezetimibe monotherapy in children with heterozygous familial or nonfamilial hypercholesterolemia. J. Pediatr. 166 (2015), 1377–1384 e1-3.
182. [182] Auwerx, J., Schoonjans, K., Fruchart, J.C., Staels, B., Transcriptional control of triglyceride metabolism: fibrates and fatty acids change the expression of the lpl and apo c-iii genes by activating the nuclear receptor ppar. Atherosclerosis 124:Suppl (1996), S29–S37.
183. [183] Steinmetz, J., Morin, C., Panek, E., Siest, G., Drouin, P., Biological variations in hyperlipidemic children and adolescents treated with fenofibrate. Clin. Chim. Acta 112 (1981), 43–53.
184. [184] Smalley, C.M., Goldberg, S.J., A pilot study in the efficacy and safety of gemfibrozil in a pediatric population. J. Clin. Lipidol. 2 (2008), 106–111.
185. [185] Kennedy, M.J., Jellerson, K.D., Snow, M.Z., Zacchetti, M.L., Challenges in the pharmacologic management of obesity and secondary dyslipidemia in children and adolescents. Paediatr. Drugs 15 (2013), 335–342.
186. [186] West, R.J., Lloyd, J.K., Leonard, J.V., Long-term follow-up of children with familial hypercholesterolaemia treated with cholestyramine. Lancet 2 (1980), 873–875.
187. [187] Stein, E.A., Marais, A.D., Szamosi, T., Raal, F.J., Schurr, D., Urbina, E.M., Hopkins, P.N., Karki, S., Xu, J., Misir, S., Melino, M., Colesevelam hydrochloride: efficacy and safety in pediatric subjects with heterozygous familial hypercholesterolemia. J. Pediatr. 156 (2010), 231–236 (e1-3).
188. [188] Colesevelam, Perry C.M., In pediatric patients with heterozygous familial hypercholesterolemia. Paediatr. Drugs 12 (2010), 133–140.
189. [189] Davidson, M.H., A systematic review of bile acid sequestrant therapy in children with familial hypercholesterolemia. J. Clin. Lipidol. 5 (2011), 76–81.
190. [190] Puri, M., Flynn, J.T., Management of hypertension in children and adolescents with the metabolic syndrome. J. Cardiometab. Syndr. 1 (2006), 259–268.
191. [191] Hall, J.E., The kidney, hypertension, and obesity. Hypertension 41 (2003), 625–633.
192. [192] Asfaha, S., Padwal, R., Antihypertensive drugs and incidence of type 2 diabetes: evidence and implications for clinical practice. Curr. Hypertens. Rep. 7 (2005), 314–322.
193. [193] Martinez-Martin, F.J., Rodriguez-Rosas, H., Peiro-Martinez, I., Soriano-Perera, P., Pedrianes-Martin, P., Comi-Diaz, C., Olmesartan/amlodipine vs olmesartan/hydrochlorothiazide in hypertensive patients with metabolic syndrome: the olas study. J. Hum. Hypertens. 25 (2011), 346–353.
194. [194] Verdecchia, P., Angeli, F., Reboldi, G.P., Gattobigio, R., New-onset diabetes in treated hypertensive patients. Curr. Hypertens. Rep. 7 (2005), 174–179.
195. [195] Kramer, C.K., Leitao, C.B., Pinto, L.C., Canani, L.H., Azevedo, M.J., Gross, J.L., Efficacy and safety of topiramate on weight loss: a meta-analysis of randomized controlled trials. Obes. Rev. 12 (2011), e338–47.
196. [196] Rothman, R.B., Baumann, M.H., Dersch, C.M., Romero, D.V., Rice, K.C., Carroll, F.I., Partilla, J.S., Amphetamine-type central nervous system stimulants release norepinephrine more potently than they release dopamine and serotonin. Synapse 39 (2001), 32–41.
197. [197] Siebenhofer, A., Jeitler, K., Horvath, K., Berghold, A., Posch, N., Meschik, J., Semlitsch, T., Long-term effects of weight-reducing drugs in people with hypertension. Cochrane Database Syst. Rev., 3, 2016, CD007654.
198. [198] Yanovski, S.Z., Yanovski, J.A., Long-term drug treatment for obesity: a systematic and clinical review. JAMA 311 (2014), 74–86.
199. [199] Star, K., Detecting unexpected adverse drug reactions in children. Paediatr. Drugs 13 (2011), 71–73.
200. [200] Brown, E.G., Wood, L., Wood, S., The medical dictionary for regulatory activities (meddra). Drug Saf. 20 (1999), 109–117.
201. [201] International conference on harmonisation; guidance on e11 clinical investigation of medicinal products in the pediatric population; availability. Notice. Fed. Regist. 65 (2000), 78493–78494.
202. [202] Watts, G.F., Gidding, S., Wierzbicki, A.S., Toth, P.P., Alonso, R., Brown, W.V., Bruckert, E., Defesche, J., Lin, K.K., Livingston, M., Mata, P., Parhofer, K.G., Raal, F.J., Santos, R.D., Sijbrands, E.J., Simpson, W.G., Sullivan, D.R., Susekov, A.V., Tomlinson, B., Wiegman, A., Yamashita, S., Kastelein, J.J., Integrated guidance on the care of familial hypercholesterolaemia from the international fh foundation. Int. J. Cardiol. 171 (2014), 309–325.
203. [203] Tonstad, S., Ose, L., Colestipol tablets in adolescents with familial hypercholesterolaemia. Acta Paediatr. 85 (1996), 1080–1082.
204. [204] McCrindle, B.W., Helden, E., Cullen-Dean, G., Conner, W.T., A randomized crossover trial of combination pharmacologic therapy in children with familial hyperlipidemia. Pediatr. Res. 51 (2002), 715–721.
205. [205] Wheeler, K.A., West, R.J., Lloyd, J.K., Barley, J., Double blind trial of bezafibrate in familial hypercholesterolaemia. Arch. Dis. Child 60 (1985), 34–37.
206. [206] Gagne, C., Gaudet, D., Bruckert, E., Efficacy and safety of ezetimibe coadministered with atorvastatin or simvastatin in patients with homozygous familial hypercholesterolemia. Circulation 105 (2002), 2469–2475.
207. [207] Colletti, R.B., Neufeld, E.J., Roff, N.K., McAuliffe, T.L., Baker, A.L., Newburger, J.W., Niacin treatment of hypercholesterolemia in children. Pediatrics 92 (1993), 78–82.
208. [208] Armani, A., Toth, P.P., Colesevelam hydrochloride in the management of dyslipidemia. Expert Rev. Cardiovasc. Ther. 4 (2006), 283–291.
209. [209] Overbeek, W.A., de Vroede, M.A., Lahuis, B.E., Hillegers, M.H., de Graeff-Meeder, E.R., Antipsychotics and metabolic abnormalities in children and adolescents: a review of the literature and some recommendations. Tijdschr. Psychiatr. 52 (2010), 311–320.
210. [210] McDuffie, J.R., Calis, K.A., Uwaifo, G.I., Sebring, N.G., Fallon, E.M., Hubbard, V.S., Yanovski, J.A., Three-month tolerability of orlistat in adolescents with obesity-related comorbid conditions. Obes. Res. 10 (2002), 642–650.
211. [211] Chanoine, J.P., Hampl, S., Jensen, C., Boldrin, M., Hauptman, J., Effect of orlistat on weight and body composition in obese adolescents: a randomized controlled trial. JAMA 293 (2005), 2873–2883.
212. [212] Wiegand, S., l'Allemand, D., Hubel, H., Krude, H., Burmann, M., Martus, P., Gruters, A., Holl, R.W., Metformin and placebo therapy both improve weight management and fasting insulin in obese insulin-resistant adolescents: a prospective, placebo-controlled, randomized study. Eur. J. Endocrinol. 163 (2010), 585–592.
213. [213] Yanovski, J.A., Krakoff, J., Salaita, C.G., McDuffie, J.R., Kozlosky, M., Sebring, N.G., Reynolds, J.C., Brady, S.M., Calis, K.A., Effects of metformin on body weight and body composition in obese insulin-resistant children: a randomized clinical trial. Diabetes 60 (2011), 477–485.
214. [214] Kendall, D., Vail, A., Amin, R., Barrett, T., Dimitri, P., Ivison, F., Kibirige, M., Mathew, V., Matyka, K., McGovern, A., Stirling, H., Tetlow, L., Wales, J., Wright, N., Clayton, P., Hall, C., Metformin in obese children and adolescents: the moca trial. J. Clin. Endocrinol. Metab 98 (2013), 322–329.
215. [215] Gungor, N.K., Overweight and obesity in children and adolescents. J. Clin. Res. Pediatr. Endocrinol. 6 (2014), 129–143.
216. [216] Soffer, B., Zhang, Z., Miller, K., Vogt, B.A., Shahinfar, S., A double-blind, placebo-controlled, dose-response study of the effectiveness and safety of lisinopril for children with hypertension. Am. J. Hypertens. 16 (2003), 795–800.
217. [217] Wells, T., Frame, V., Soffer, B., Shaw, W., Zhang, Z., Herrera, P., Shahinfar, S., A double-blind, placebo-controlled, dose-response study of the effectiveness and safety of enalapril for children with hypertension. J. Clin. Pharmacol. 42 (2002), 870–880.
218. [218] Li, J.S., Berezny, K., Kilaru, R., Hazan, L., Portman, R., Hogg, R., Jenkins, R.D., Kanani, P., Cottrill, C.M., Mattoo, T.K., Zharkova, L., Kozlova, L., Weisman, I., Deitchman, D., Califf, R.M., Is the extrapolated adult dose of fosinopril safe and effective in treating hypertensive children. Hypertension 44 (2004), 289–293.
219. [219] Shahinfar, S., Cano, F., Soffer, B.A., Ahmed, T., Santoro, E.P., Zhang, Z., Gleim, G., Miller, K., Vogt, B., Blumer, J., Briazgounov, I., A double-blind, dose-response study of losartan in hypertensive children. Am. J. Hypertens. 18 (2005), 183–190.
220. [220] Trachtman, H., Hainer, J.W., Sugg, J., Teng, R., Sorof, J.M., Radcliffe, J., Efficacy, safety, and pharmacokinetics of candesartan cilexetil in hypertensive children aged 6 to 17 years. J. Clin. Hypertens. (Greenwich) 10 (2008), 743–750.
221. [221] Flynn, J.T., Meyers, K.E., Neto, J.P., de Paula Meneses, R., Zurowska, A., Bagga, A., Mattheyse, L., Shi, V., Gupte, J., Solar-Yohay, S., Han, G., Efficacy and safety of the angiotensin receptor blocker valsartan in children with hypertension aged 1 to 5 years. Hypertension 52 (2008), 222–228.
222. [222] Flynn, J.T., Newburger, J.W., Daniels, S.R., Sanders, S.P., Portman, R.J., Hogg, R.J., Saul, J.P., A randomized, placebo-controlled trial of amlodipine in children with hypertension. J. Pediatr. 145 (2004), 353–359.
223. [223] Sorof, J.M., Cargo, P., Graepel, J., Humphrey, D., King, E., Rolf, C., Cunningham, R.J., Beta-blocker/thiazide combination for treatment of hypertensive children: a randomized double-blind, placebo-controlled trial. Pediatr. Nephrol. 17 (2002), 345–350.
224. [224] Lavine, J.E., Schwimmer, J.B., Molleston, J.P., Scheimann, A.O., Murray, K.F., Abrams, S.H., Rosenthal, P., Sanyal, A.J., Robuck, P.R., Brunt, E.M., Unalp, A., Tonascia, J., Treatment of nonalcoholic fatty liver disease in children: tonic trial design. Contemp. Clin. Trials 31 (2010), 62–70.
225. [225] Pellegrino, P., Carnovale, C., Cattaneo, D., Perrone, V., Antoniazzi, S., Pozzi, M., Napoleone, E., Filograna, M.R., Clementi, E., Radice, S., Pharmacovigilance knowledge in family paediatricians. A survey study in Italy. Health Policy 113 (2013), 216–220.
226. [226] Inman, W.H., Attitudes to adverse drug reaction reporting. Br. J. Clin. Pharmacol. 41 (1996), 434–435.
227. [227] Hazell, L., Shakir, S.A., Under-reporting of adverse drug reactions: a systematic review. Drug Saf. 29 (2006), 385–396.
228. [228] Plan and operation of the Third National Health and Nutrition Examination Survey, 1988–94. Series 1: programs and collection procedures. Vital Health Stat, vol. 1, 1994, 1–407.
229. [229] Update on the 1987 task force report on high blood pressure in children and adolescents: a working group report from the national high blood pressure education program. national high blood pressure education program working group on hypertension control in children and adolescents. Pediatrics 98 (1996), 649–658.
230. [230] Executive summary of the Third Report of The National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (adult treatment panel III). JAMA 285 (2001), 2486–2497.
231. [231] de Ferranti, S.D., Gauvreau, K., Ludwig, D.S., Neufeld, E.J., Newburger, J.W., Rifai, N., Prevalence of the metabolic syndrome in American adolescents: findings from the Third National Health and Nutrition Examination Survey. Circulation 110 (2004), 2494–2497.
232. [232] Cruz, M.L., Weigensberg, M.J., Huang, T.T., Ball, G., Shaibi, G.Q., Goran, M.I., The metabolic syndrome in overweight Hispanic youth and the role of insulin sensitivity. J. Clin. Endocrinol. Metab. 89 (2004), 108–113.
233. [233] Hickman, T.B., Briefel, R.R., Carroll, M.D., Rifkind, B.M., Cleeman, J.I., Maurer, K.R., Johnson, C.L., Distributions and trends of serum lipid levels among United States children and adolescents ages 4–19 years: data from the Third National Health and Nutrition Examination Survey. Prev. Med. 27 (1998), 879–890.
234. [234] American Diabetes Association: clinical practicerecommendations 2002. Diabetes Care 25:Suppl. 1 (2002), S1–S147.
235. [235] Ford, E.S., Ajani, U.A., Mokdad, A.H., The metabolic syndrome and concentrations of C-reactive protein among U.S. youth. Diabetes Care 28 (2005), 878–881.
236. [236] Cole, T.J., Freeman, J.V., Preece, M.A., Body mass index reference curves for the UK, 1990. Arch. Dis. Child 73 (1995), 25–29.
237. [237] Report of the second task force on blood pressure control in children–1987. task force on blood pressure control in children. National Heart, Lung, and Blood Institute, Bethesda, Maryland. Pediatrics 79 (1987), 1–25.
238. [238] Goodman, E., Daniels, S.R., Meigs, J.B., Dolan, L.M., Instability in the diagnosis of metabolic syndrome in adolescents. Circulation 115 (2007), 2316–2322.
239. [239] The fourth report on the diagnosis, evaluation, and treatment of high blood pressure in children and adolescents. Pediatrics 114 (2007), 555–576.
240. [240] Nagy, P., Kovacs, E., Moreno, L.A., Veidebaum, T., Tornaritis, M., Kourides, Y., Siani, A., et al. Percentile reference values for anthropometric body composition indices in European children from the IDEFICS study. Int. J. Obes. (Lond.) 38:Suppl. 2 (2014), S15–S25.
241. [241] De Henauw, S., Michels, N., Vyncke, K., Hebestreit, A., Russo, P., Intemann, T., Peplies, J., et al. Blood lipids among young children in Europe: results from the European IDEFICS study. Int. J. Obes. (Lond.) 38:Suppl. 2 (2014), S67–S75.
242. [242] Peplies, J., Jimenez-Pavon, D., Savva, S.C., Buck, C., Gunther, K., Fraterman, A., Russo, P., et al. Percentiles of fasting serum insulin, glucose, HbA1c and HOMA-IR in pre-pubertal normal weight European children from the IDEFICS cohort. Int. J. Obes. (Lond.) 38:Suppl. 2 (2014), S39–47.